PolyPid (PYPD) to Post Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $0.30 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, analysts expect PolyPid to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PolyPid Stock Performance

PYPD opened at $4.45 on Wednesday. The company has a market cap of $84.91 million, a price-to-earnings ratio of -2.33 and a beta of 1.41. PolyPid has a one year low of $3.06 and a one year high of $5.73. The business’s fifty day moving average is $4.74 and its two-hundred day moving average is $4.56.

Analyst Upgrades and Downgrades

PYPD has been the subject of several research reports. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of PolyPid in a report on Tuesday, July 21st. Finally, Craig Hallum set a $12.00 target price on shares of PolyPid in a research report on Wednesday, July 22nd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, PolyPid has an average rating of “Moderate Buy” and a consensus price target of $11.33.

Hedge Funds Weigh In On PolyPid

Several hedge funds have recently bought and sold shares of PYPD. BNP Paribas Financial Markets lifted its position in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolyPid during the fourth quarter valued at $44,000. Jane Street Group LLC purchased a new stake in PolyPid during the 4th quarter worth about $66,000. XTX Topco Ltd raised its stake in PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in PolyPid in the 4th quarter valued at about $451,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.